QualityStocksNewsBreaks Archives - Page 1203 of 1372

WednesdaySep 05, 2018 9:57 am

QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) MIDS Medical Ltd. JV Secures Up to $1.2M in Staged Funding

Zenosense (OTC: ZENO), a healthcare technology company, this morning announced that its MIDS Medical Ltd. (“MML") joint venture (“JV”) has entered a staged funding for the next phase of development of the MIDS Cardiac™ hand-held technology. MML entered into an agreement with a third-party investor for funding of up to a total of $1,200,000 on August 31, 2018. The funding is anticipated to cover the expenses of the next key development phase intended to prove that the MIDS magnetic detection method can detect and accurately quantify a live high sensitivity (“HS”) assay on the MIDS microfluidic test strip. Per the…

WednesdaySep 05, 2018 9:17 am

QualityStocksNewsBreaks – Hunter Oil Corp. (TSX.V: HOC) (OTCQX: HOILF) to Pay Return of Capital Distribution to Shareholders of Record

Hunter Oil (TSX.V: HOC) (OTCQX: HOILF) recently announced that it will pay a return of capital distribution of CAD $1.625 (approximately USD $1.25) per common share of the company to all registered shareholders of record at the close of business on September 11, 2018. The distribution represents the proceeds the company received from the sale of its assets, less outstanding liabilities and USD $2,500,000 for working capital. The distribution to unregistered shareholders holding through intermediaries will be made in accordance with the “due bill” trading procedures of the TSX Venture Exchange. The purpose is to have traded shares carry the…

WednesdaySep 05, 2018 9:05 am

QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) to Develop PRO 140 as Therapy for Triple-Negative Breast Cancer

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) this morning detailed its plan to develop PRO 140 (leronlimab) as a therapy for metastatic triple-negative breast cancer. Per the update, previously announced findings from preclinical studies showed the ability of PRO 140 to block human breast cancer cellular invasion in a surrogate assay for metastatic breast cancer. “We plan to aggressively pursue the development of PRO 140 as a therapy for women with metastatic triple-negative breast cancer, which is in keeping with our strategy to evaluate PRO 140 in certain cancers and immunological indications where CCR5 antagonism has shown initial promise,” Nader Pourhassan,…

TuesdaySep 04, 2018 3:20 pm

QualityStocksNewsBreaks – Why CytoDyn Inc. (CYDY) is “One to Watch”

Biotechnology company CytoDyn (OTCQB: CYDY) is focused on the clinical development and potential commercialization of a new class of HIV/AIDS therapeutics or viral-entry inhibitors intended to protect healthy cells from viral infection. A recent article discussing the company reads: “The U.S. Food and Drug Administration has designated PRO 140 as a “fast track” product for HIV and granted Orphan Drug Designation to it for the prevention of GvHD in transplant patients. CytoDyn has initiated its first clinical trial with PRO 140 in an immunological indication for GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are…

TuesdaySep 04, 2018 2:38 pm

QualityStocksNewsBreaks – Accelerated Technologies Holding Corp. (ATHC) Receives Positive Feedback from Intelagy Launch

Accelerated Technologies Holding’s (OTC: ATHC) managing director, Alex Lemberg, recently spoke to NetworkNewsAudio’s Stuart Smith about the company’s launch of Intelagy. ATHC reported a significantly positive response to its new credit card processing solution. An article discussing the company reads: “ATHC, which provides consulting and develops technology products and services, recently launched Intelagy, which provides a range of services, including credit card processing, branding, web development and hosting solutions, to small-to-medium businesses. “Yesterday we did our first fairly decent-sized marketing campaign,” Lemberg said in the interview (http://ibn.fm/XQzgu). … Intelagy is subscription-based, meaning that merchants can choose to pay for the level…

TuesdaySep 04, 2018 2:33 pm

QualityStocksNewsBreaks – Auscrete Corp. (ASCK) Plans to Commence Production at Flagship Facility by Year-end

Auscrete (OTC: ASCK), a building products manufacturer of environmentally-friendly, energy-efficient housing and commercial structures, intends to commence production from its flagship facility in Goldendale, Washington by the end of this year. A recent article discussing the company reads: “ASCK is a building manufacturing company focused on ‘green’, energy efficient structures made from lightweight hybrid concrete/insulation wall and roof panels. The company, which is positioning itself as a major supplier in the affordable housing market, has stated that these units have very low maintenance costs. They are resistant to insects and mold, as well as natural events such as hurricanes and…

TuesdaySep 04, 2018 11:39 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Develops Proprietary Cannabinoid Extraction Protocol

Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) today announced that it has successfully optimized its extraction protocol during its soluble gel ("Sol-gel") drug delivery research and development program. The company augmented the circumstances for extracting cannabinoids from one of its cannabis strains and established a proprietary method for the accurate quantification of cannabinoids present in the extract. The accuracy and precision of the company’s extraction protocol was confirmed against eight commercial cannabinoid standards over a wide concentration range. PreveCeutical anticipates that the new protocol will accelerate the creation of a library of chemically fingerprinted cannabinoid extracts.…

TuesdaySep 04, 2018 11:23 am

QualityStocksNewsBreaks – The Flowr Corp. Announces Close of C$36M Offering

The Flowr Corp., a Canadian licensed producer that focuses primarily on premium flower production, this morning announced that it has closed its offering of subscription receipts, which was previously oversubscribed and raised approximately C$36 million. Per the update, the offering is a further step toward completing the company’s previously announced plan to effect a reverse takeover of The Needle Capital Corp., which is anticipated to occur on or before September 10. “Completing this oversubscribed offering is another exciting milestone on Flowr’s journey to producing the finest cannabis experience in the world as well as an acknowledgement of investors’ belief in…

TuesdaySep 04, 2018 10:48 am

QualityStocksNewsBreaks – Earth Science Tech, Inc. (ETST) Reaches Fully Reporting Status with the SEC

Biotechnology company Earth Science Tech (OTC: ETST) this morning announced its Form 10 filing effective date of August 29, 2018, making the company fully reporting with the Security Exchange Commission (“SEC”). ETST is now subject to the reporting requirements of the Exchange Act of 1934, as amended. “With our Form 10 filing now effective, ETST is progressing towards fulfilling its goals,” Earth Science Tech president, director and Chairman Nickolas S. Tabraue stated in the news release. “Following this achievement, we anticipate to up-list to the OTCQB tier in early September, due to our early application submission with OTC Markets Group,…

Site Search

Company Search

Category: QualityStocksNewsBreaks